Dialectic Therapeutics, Inc.

DALLAS, TX · Founded 2018 · Biotech · Private

Targeted cancer therapeutics using novel drug development technologies

Claim this profile

Follows are private to you and power your alerts

Updated · dtsciences.com

Sector
Biotech
Headquarters
DALLAS, TX
Founded
2018
Latest Form D
$2.9M, Dec 2020
Total capital
$5.4M
Federal grants
None on recordNo awards found in SBIR/STTR, NIH, NSF or DoD records.
Private capital raised
$5.4M
3 Form D · last Dec 2020
70 months since last filing
Federal contracts
None on recordNo federal contract awards found.
Granted patents
0
5 pending

Capital timeline

201820192020FEDERAL ↑EQUITY ↓Cumulative $5.4M1st Form D$2M2nd Form D$500K
201820192020FEDERAL ↑EQUITY ↓Cumulative $5.4M1st Form D$2M2nd Form D$500K

Latest events

  • Private capital raisedForm D · SEC · 3rd filing$2.9M
  • Private capital raisedForm D · SEC · 2nd filing$500K
  • Private capital raisedForm D · SEC · 1st filing$2M

Node area is scaled to amount. Form D reports securities sold, which can differ from an announced round; filings are numbered in the order they were made.

Founders and team

From SEC Form D filings
  • Daohong ZhouExecutive Officer, DirectorNamed in SEC Form D filings
  • David GenecovDirectorNamed in SEC Form D filings
  • John D. HarkeyDirectorNamed in SEC Form D filings
  • Joshua D. SillsExecutive OfficerNamed in SEC Form D filings
  • Robert HromasDirectorNamed in SEC Form D filings

What it has protected

USPTO · 0 granted of 5
  • PendingSmall Molecule FormulationUSPTOApplication 18035923
  • PendingCombination Therapies For The Treatment Of Advanced Malignancies Including Solid TumorsUSPTOApplication PCTUS2025043040
  • PendingCombination Therapies For The Treatment Of Advanced Malignancies Including Solid TumorsUSPTOApplication 63687577
Show all 5 patent records
  • Small Molecule FormulationJan 11, 2024 · Application 18035923Pending
  • Combination Therapies For The Treatment Of Advanced Malignancies Including Solid TumorsApplication PCTUS2025043040Pending
  • Combination Therapies For The Treatment Of Advanced Malignancies Including Solid TumorsApplication 63687577Pending
  • Small Molecule FormulationApplication PCTUS2021058843Pending
  • Small Molecule FormulationApplication 63112132Pending
  • Outpost Medicine, LLCSimilar federal contract value in Biotech · null in contracts
  • AI Proteins, Inc.Similar federal contract value in Biotech · null in contracts
  • FibroGenSimilar federal contract value in Biotech · null in contracts
  • Propanc Biopharma, Inc.Similar federal contract value in Biotech · null in contracts
  • CHINA PHARMA HOLDINGS, INC.Similar federal contract value in Biotech · null in contracts
  • iToleranceSimilar federal contract value in Biotech · null in contracts

Regulatory activity · Biotech

Sector-level, not company-level

Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.

Sources

Federal grants from SBIR/STTR, NIH, NSF and DoD records. Federal contracts from USAspending.gov. Private capital from SEC Form D. Patents from USPTO. Publications from OpenAlex. Regulatory activity from the Federal Register. Press matched on company name.

How to read this page

Figures show associations in public records, not causes or predictions. Nothing here is investment advice. An em-dash means no record was found under this company's name, not that none exists.

Data freshness

SEC Form D filings through . SBIR and STTR awards through .